Skip to main content

Advertisement

Table 2 Frequency and latency of induced tumors

From: Impairment of alternative splice sites defining a novel gammaretroviral exon within gagmodifies the oncogenic properties of Akv murine leukemia virus

Virus FBL DLBCL (progression from FBL) De novoDLBCL# PCT SMZL DLBCL (progression from SMZL) SBL PTLL STL Histiocytic sarcoma
Akv-wt 9/40 (23%) 13/40 (33%) 0/40 (0%) 13/40 (33%) 3/40 (8%) 0/40 (0%) 2/40 (5%) 0/40 (0%) 0/40 (0%) 0/40 (0%)
Akv-CD* 0/18 (0%) 7/18 (39%) 0/18 (0%) 1/18 (6%) 5/18 (28%) 1/18 (6%) 0/18 (0%) 0/18 (0%) 0/18 (0%) 4/18 (22%)
Akv-EH 1/17 (6%) 4/17 (24%) 6/17 (35%) 3/17 (18%) 0/17 (0%) 1/17 (6%) 0/17 (0%) 0/17 (0%) 1/17 (6%) 0/17 (0%)
Akv-CDH 1/14 (7%) 5/14 (36%) 0/14 (0%) 5/14 (36%) 0/14 (0%) 0/14 (0%) 0/14 (0%) 1/14 (7%) 0/14 (0%) 0/14 (0%)
Total 11/88 (13%) 29/88 (33%) 6/88 (7%) 22/88 (25%) 8/88 (9%) 2/88 (2%) 2/88 (2%) 1/88 (1%) 1/88 (1%) 4/88 (5%)
Av. latency period (days) 188 ± 30 198 ± 31 187 ± 43 180 ± 27 207 ± 20 174 ± 18 153 ± 12 107 146 211 ± 36
  1. Abbreviations: FBL, follicular B cell lymphoma; DLBCL, diffuse large B cell lymphoma; PCT, plasmacytoma; SMZL, splenic marginal zone lymphoma; SBL, small B cell lymphoma; PTLL, precursor T cell lymphoblastic lymphoma; STL, small T-cell lymphoma.
  2. # De novo DLBCL refers to Bethesda classification "DLBCL centroblastic"; however, to stress the parallel to human de novo lymphomas we use this term.
  3. *In this group one of the 17 mice that developed tumors had two tumors, hence a total number of 18 tumors.